Royalty Report: Medical, Device, Surgical – Collection: 1940

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 15

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 15

Primary Industries

  • Medical
  • Device
  • Surgical
  • Ophthalmological
  • Diagnostic
  • Scientific & Technical Instruments
  • Delivery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 1940

License Grant
The Company acquired the technology for its continuous-wave laser catheter system in 1989; tachycardia devices from the Licensor, two individuals.

IPSCIO Record ID: 1941

License Grant
The Company has agreed to pay doctors' efforts in connection with the laser catheter ablation system.

IPSCIO Record ID: 375426

License Grant
The Licensee acquired certain intellectual property from an undisclosed Licensor to be used in the development of the ALLY Adaptive Cataract Treatment System.
License Property
ALLY Adaptive Cataract Treatment System is designed to combine our existing femtosecond laser technology with enhanced capabilities and a phacoemulsification system into a single unit and allow surgeons to perform each of the critical steps in a cataract procedure in a single operating room using this device.
Field of Use
The rights acquired are for laser technology in a device used by medical surgeons in a cataract procedure.

IPSCIO Record ID: 203456

License Grant
Attached to this settlement agreement, the Licensor grants a worldwide non-exclusive license under Licensors Patent Rights and Know-how to make, have made for it, use, and sell Licensed Products. The license granted herein is expressly limited to the specific Licensed Products defined herein, and does not include the right to sublicense except to an Affiliate.

This license granted for Laser Angioplasty Catheters is non-cancelable by Licensee during the period from the Effective Date through June 30, 2009.

This license granted for Non-Laser Functioning Catheters and Guidewires for use with Licensees Laser Therapy Systems is non-exclusive.

License Property
The licensors patents include, but are not limited to, Method of Improving the Biocompatibility of Solid Surfaces, Surface Coating Agents and Substrate Surface Preparation.

The Licensed Products means Medical Products that are surface-treated with photoreactive polyvinylpyrrolidone copolymer, non-photoreactive polyvinylpyrrolidone, photoreactive polyacrylamide copolymer, one or more of the photoreactive crosslinking agents known to the parties as PR01 and PR04, a compound for promoting polymer-to-metal adhesion known to the parties as TL03, or any combination of these compounds, for the purpose of providing a lubricious surface to the Medical Products.

MEDICAL PRODUCTS-B1 Laser Angioplasty Catheters
The Medical Products means excimer laser angioplasty catheters specifically adapted for coronary and peripheral use. Medical Products includes Licensees chronic total occlusion laser angioplasty catheters.

MEDICAL PRODUCTS-B2 Non-Laser Functioning Catheters and Guidewires for use with Spectranetics Laser Therapy Systems
The Medical Products means the following Licensee-labeled non-laser functioning catheters and guidewires for Licensees laser therapy system that are specifically designed and labeled for use solely with laser angioplasty catheters (I) BIAS sheath, (ii) support catheters, (iii) cardiac lead locking device, and (iv) chronic total occlusion steerwires.  Medical Products does not include catheters for (I) infusion of diagnostic, therapeutic, or embolic agents in the neurovascular region, or (ii) insertion of therapeutic embolic devices in the neurovascular region. Medical Products does not include catheters used to deliver stents of any type.

Field of Use
Licensee designs, manufactures, markets and distributes single-use medical devices used in minimally invasive surgical procedures within the vascular system in conjunction with our proprietary excimer laser system.

IPSCIO Record ID: 257712

License Grant
The Licensee is obligated under the License Agreement to pay a royalty on the net sales of its  dual  use uterine monitoring catheter, AmCath,  to the Inventors, two individuals.
License Property
The dual use uterine monitoring catheter, AmCath, that allows simultaneous measurement of interuterine pressure during labor and a means for administering sterile isotonic solution.
Field of Use
The Licensee strives to develop new products in the areas of the medical device industry.

IPSCIO Record ID: 5091

License Grant
The Licensee also has the exclusive right to distribute and manufacture the Company’s Trio/Ensemble diagnostic catheters in all territories of the world except southern Europe and Japan.
License Property
The Trio/Ensemble catheters are used for electrophysiological diagnostic mapping of supraventricular tachycardia (SVT), a congenital, rapid heart rhythm that originates above the ventricles in the heart. Using the Trio/Ensemble diagnostic catheters, the electrophysiologist is able to place three catheters through a single patient introduction site rather than having to use three separate introduction sites.  In this way, the Trio/Ensemble provides the electrophysiologist with an overall tool to assess electrical conduction between the atria and the ventricle. Once the SVT is mapped, it can readily be treated using standard radio frequency (RF) catheter ablation techniques to neutralize the heart tissue responsible for the abnormal heart rhythm.
Field of Use
The rights are granted to be used for electrophysiological diagnostic mapping of supraventricular tachycardia (SVT), a congenital, rapid heart rhythm that originates above the ventricles in the heart.

IPSCIO Record ID: 1975

License Grant
The Company licensed it intellectual laser properties; patented ultrafast laser systems for the treatment of a broad range of eye disorders.
License Property
Licensor’s solid-state pico-second (one trillionth of a second) Nd YLF (NeodymiumYitrium-Lithium-Fluoride) laser systems are designed to be more precise than lasers systems utilizing currently available technologies.
Field of Use
The rights granted apply to the healthcare market specializing in ophthalmic medical devices.

IPSCIO Record ID: 7652

License Grant
The Licensor granted the undisclosed Licensee the use of the laser patents.
License Property
The Licensor technology involves ophthalmic lasers which may be used in the laser eye-surgery market.

IPSCIO Record ID: 118680

License Grant
Licensor granted us a non-exclusive license to its patent covering excimer laser ablation of tissue.  The terms of the license permit us to sublicense our subsidiaries.
License Property
The excimer laser systems and related products are used to perform procedures that correct common refractive vision disorders such as nearsightedness, farsightedness and astigmatism.
Field of Use
Laser vision correction is a surgical procedure for correcting disorders such as nearsightedness, farsightedness and astigmatism using an excimer laser. This procedure uses ultraviolet laser energy to remove tissue from the surface of, and thus sculpt, the cornea into a predetermined shape. Because the excimer laser is a cold laser, it is possible to ablate, or remove precise amounts of corneal tissue without causing thermal damage to surrounding tissue. The goal of laser vision correction is to eliminate or reduce a persons reliance on corrective eyewear.

IPSCIO Record ID: 27310

License Grant
The Company entered into agreements for its laser technology for reshaping human eyes.
License Property
The technology allows physicians to re-contour the cornea to adjust for vision impairments, thus eliminating the need for glasses or contact lenses.

IPSCIO Record ID: 2681

License Grant
The Licensee entered into a settlement Agreement with the Licensor, an individual, for the dismissal of a lawsuit. Under the terms of the settlement Agreement, the Licensee agree to provide the Licensor with the exclusive right over a three-year period to market and sell our Photon(TM) laser system and its components, including the inventory and intellectual property rights. If Dr. Spadafora is successful in finding a prospective purchaser to acquire the Photon(TM) laser system upon terms acceptable to us, we agree to pay him a commission equal to a percentage of the total purchase price. If the purchase price for the Photon(TM) laser system includes a royalty or other payments payable to us on later sales of the Photon(TM) laser system other than its hand piece component, we agree to pay Dr. Spadafora a percentage of such royalties or other payments on such later sales through the full term of the purchase Agreement. We further agree that if a purchase price includes a royalty or other payments payable to us on later sales of the hand piece component of the Photon(TM) laser system, we agree to pay Dr. Spadafora a percentage of such royalties or other payments through the full term of the purchase Agreement. Additionally, the settlement Agreement provides that if we are successful through our sole efforts, without any assistance from Dr. Spadafora, in finding a purchaser to acquire the Photon(TM) laser system or its components during the second or third year of Dr. Spadafora's exclusive rights, we agree to pay Dr. Spadafora a commission equal to a percentage of the total purchase price and of our royalties or other payments on subsequent sales of the Photon(TM) laser system or its components through the full term of the purchase Agreement. Finally, the settlement Agreement provides for mutual releases by Dr. Spadafora and us for the benefit of each other, and that we each agree to pay our own costs, expenses and attorney's fees incurred in connection with the lawsuit and the preparation of the settlement.
Field of Use
The Licensee has developed the Photon(TM) laser system, a laser cataract surgery system using a unique patented probe for minimally invasive cataract treatment, which the Licensee markets as the next generation of cataract removal based on United States Patent No. 6,454,763.

IPSCIO Record ID: 714

License Grant
Licensor, an individual, hereby grants to Licensee a world-wide exclusive, nontransferable, personal, sublicenseable only to those companies against which Licensee enforces the Rentrop Patents pursuant to this Agreement, revocable, royalty-bearing license under the Rentrop Patents to make, use, offer for sale, import, sell, or otherwise dispose of Licensed Catheters.
Licensor hereby grants to the Licensee a world-wide exclusive, nontransferable, personal, subLicenseable, as a result of the litigation in the U.S. District Court for the Southern District of New York. The Litigation was tried to the jury, resulting in a jury verdict on December 8, 2006 of infringement of claims 1, 8, and 15-17 of U.S. Patent Nos. 6,673,064. The License granted under this Agreement shall continue in full force and effect from the effective date until January 4, 2020.
License Property
Licensor is the sole inventor of and owns all right, title, and interest in and to U.S. Patent Nos. 6,440,125 and 6,673,064 and any applications claiming priority thereto.

IPSCIO Record ID: 3990

License Grant
The Foundation owns the Licensable Technology as defined. The Optionee specializes in developing technology and bringing new technologies to market; and desires to investigate and conduct due diligence with respect to the commercial viability of the Licensable Technology prior to executing the License Agreement.
License Property
'Licensable Patents' shall refer to and mean US Patent Application # 60/797,433 entitled 'Intra-jugular Catheter' and any U.S. or foreign patent applications, reissues, extensions, renewals, reexaminations, certificates of invention, substitutions, divisions, continuations, and continuations-in-part thereof having the Principal Investigator as an inventor and having the same priority date as the parent applications. The Field shall mean clinical use as a catheter for insertion into the vascular system of a patient to direct fluid flow, sampling of fluids and oxygenation monitoring.
Field of Use
'Field' shall mean clinical use as a catheter for insertion into the vascular system of a patient to direct fluid flow, sampling of fluids and oxygenation monitoring.

IPSCIO Record ID: 4797

License Grant
The Company acquired a semi-exclusive worldwide license with the Licensor, an individual, to the rights to certain technology for a Temporary Ventricular Defibrillation Catheter and Treatment Method.

IPSCIO Record ID: 1850

License Grant
The Company entered into an agreement for the license for Epidural catheters used to infuse drugs into the epidural space in the spinal column (vi) Implantable infusion ports and pumps and their attached catheters used for drug therapy and access to the vascular system (vii) Intra-aortic balloon catheters (viii) Drainage catheters used to drain chest cavities, surgical incisions, wounds and abscesses.
Field of Use
Fields of Application)
(v) Epidural catheters used to infuse drugs into the epidural space in the spinal column.
(vi) Implantable infusion ports and pumps and their attached catheters used for drug therapy and access to the vascular system.
(vii) Intra-aortic balloon catheters.
(viii) Drainage catheters used to drain chest cavities, surgical incisions, wounds and abscesses.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.